Follow the people · Insider
Erick Lucera
Erick Lucera files insider transactions with the SEC as a chief financial officer of Dyne Therapeutics (DYN). We hold 4 disclosed purchases and sales filed since 27 March 2017, 2 of them in the last 90 days.
- Files forDYN
- Disclosed buys and sells4 in all, 2 in the last 90 days
- Last disclosure17 August 2026
Positions held
8 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 31 March 2025 — 13 August 2026Chief Financial Officer · Dyne Therapeutics (DYN)10 Form 4 lines · source: SEC Form 4
- Filed 3 April 2023 — 16 December 2025Director · SAB Biotherapeutics (SABS)3 Form 4 lines · source: SEC Form 4
- Filed 16 February 2021 — 4 November 2025Director · Beyond Air (XAIR)39 Form 4 lines · source: SEC Form 4
- Filed 17 May 2023 — 8 March 2025EVP, Chief Financial Officer · Editas Medicine (EDIT)9 Form 4 lines · source: SEC Form 4
- Filed 26 October 2021 — 18 September 2023Director · Bone Biologics (BBLG)4 Form 4 lines · source: SEC Form 4
- Filed 6 January 2020 — 19 January 2023Chief Financial Officer · Aveo Pharmaceuticals (AVEO)6 Form 4 lines · source: SEC Form 4
- Filed 23 March 2017 — 7 March 2019Officer · Valeritas Holdings (VLRX)7 Form 4 lines · source: SEC Form 4
- Filed 16 February 2018 — 13 August 2018Director · AIT Therapeutics (AITB)5 Form 4 lines · source: SEC Form 4
Everything they disclosed
83 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 1,797 shares of Dyne TherapeuticsSEC Form 417 August 2026Common Stock · traded 13 August 2026 · filed 17 August 2026
- ▼ sold on the open market 2,362 shares of Dyne TherapeuticsSEC Form 426 June 2026Common Stock · traded 25 June 2026 · filed 26 June 2026
- ▼ sold on the open market 1,448 shares of Dyne TherapeuticsSEC Form 414 May 2026Common Stock · traded 13 May 2026 · filed 14 May 2026
- ▼ sold on the open market 5,727 shares of Dyne TherapeuticsSEC Form 43 April 2026Common Stock · traded 1 April 2026 · filed 3 April 2026
- was granted 65,000 shares of Dyne TherapeuticsSEC Form 417 February 2026Common Stock · traded 12 February 2026 · filed 17 February 2026
- was granted 105,000 shares of Dyne Therapeutics (a derivative holding)SEC Form 417 February 2026Stock Option (Right to Buy) · traded 12 February 2026 · filed 17 February 2026
- was granted 105,000 shares of Dyne Therapeutics (a derivative holding)SEC Form 417 February 2026Stock Option (Right to Buy) · traded 12 February 2026 · filed 17 February 2026
- was granted 65,000 shares of Dyne TherapeuticsSEC Form 417 February 2026Common Stock · traded 12 February 2026 · filed 17 February 2026
- was granted 150,000 shares of SAB Biotherapeutics (a derivative holding)SEC Form 418 December 2025Stock option (right to buy) · traded 16 December 2025 · filed 18 December 2025
- returned to the issuer 2,250 shares of Beyond Air (a derivative holding)SEC Form 46 November 2025Stock Options (Right to buy) · traded 4 November 2025 · filed 6 November 2025
- was granted 2,250 shares of Beyond Air (a derivative holding)SEC Form 46 November 2025Stock Options (Right to buy) · traded 4 November 2025 · filed 6 November 2025
- returned to the issuer 2,000 shares of Beyond Air (a derivative holding)SEC Form 46 November 2025Stock Options (Right to buy) · traded 4 November 2025 · filed 6 November 2025
- was granted 2,000 shares of Beyond Air (a derivative holding)SEC Form 46 November 2025Stock Options (Right to buy) · traded 4 November 2025 · filed 6 November 2025
- returned to the issuer 1,500 shares of Beyond Air (a derivative holding)SEC Form 46 November 2025Stock Options (Right to buy) · traded 4 November 2025 · filed 6 November 2025
- was granted 1,500 shares of Beyond Air (a derivative holding)SEC Form 46 November 2025Stock Options (Right to buy) · traded 4 November 2025 · filed 6 November 2025
- returned to the issuer 1,250 shares of Beyond Air (a derivative holding)SEC Form 46 November 2025Stock Options (Right to buy) · traded 4 November 2025 · filed 6 November 2025
- was granted 1,250 shares of Beyond Air (a derivative holding)SEC Form 46 November 2025Stock Options (Right to buy) · traded 4 November 2025 · filed 6 November 2025
- returned to the issuer 1,250 shares of Beyond Air (a derivative holding)SEC Form 46 November 2025Stock Options (Right to buy) · traded 4 November 2025 · filed 6 November 2025
- was granted 1,250 shares of Beyond Air (a derivative holding)SEC Form 46 November 2025Stock Options (Right to buy) · traded 4 November 2025 · filed 6 November 2025
- returned to the issuer 1,000 shares of Beyond Air (a derivative holding)SEC Form 46 November 2025Stock Options (Right to buy) · traded 4 November 2025 · filed 6 November 2025
- was granted 1,000 shares of Beyond Air (a derivative holding)SEC Form 46 November 2025Stock Options (Right to buy) · traded 4 November 2025 · filed 6 November 2025
- returned to the issuer 1,250 shares of Beyond Air (a derivative holding)SEC Form 46 November 2025Stock Options (Right to buy) · traded 4 November 2025 · filed 6 November 2025
- was granted 1,250 shares of Beyond Air (a derivative holding)SEC Form 46 November 2025Stock Options (Right to buy) · traded 4 November 2025 · filed 6 November 2025
- returned to the issuer 3,750 shares of Beyond Air (a derivative holding)SEC Form 46 November 2025Stock Options (Right to buy) · traded 4 November 2025 · filed 6 November 2025
- was granted 3,750 shares of Beyond Air (a derivative holding)SEC Form 46 November 2025Stock Options (Right to buy) · traded 4 November 2025 · filed 6 November 2025
- was granted 214,500 shares of Dyne Therapeutics (a derivative holding)SEC Form 41 April 2025Stock Option (Right to Buy) · traded 31 March 2025 · filed 1 April 2025
- was granted 66,100 shares of Dyne TherapeuticsSEC Form 41 April 2025Common Stock · traded 31 March 2025 · filed 1 April 2025
- was granted 75,000 shares of Beyond Air (a derivative holding)SEC Form 428 March 2025Stock Options (Right to buy) · traded 26 March 2025 · filed 28 March 2025
- was granted 275,100 shares of Editas Medicine (a derivative holding)SEC Form 427 March 2025Stock Option (right to buy) · traded 8 March 2025 · filed 27 March 2025
- was granted 70,000 shares of Editas Medicine (a derivative holding)SEC Form 427 March 2025Stock Option (right to buy) · traded 8 March 2025 · filed 27 March 2025
- ▼ sold on the open market 4,109 shares of Editas MedicineSEC Form 45 March 2025Common Stock · traded 4 March 2025 · filed 5 March 2025
- returned to the issuer 45,000 shares of Beyond Air (a derivative holding)SEC Form 426 November 2024Stock Options (Right to buy) · traded 22 November 2024 · filed 26 November 2024
- was granted 45,000 shares of Beyond Air (a derivative holding)SEC Form 426 November 2024Stock Options (Right to buy) · traded 22 November 2024 · filed 26 November 2024
- returned to the issuer 40,000 shares of Beyond Air (a derivative holding)SEC Form 426 November 2024Stock Options (Right to buy) · traded 22 November 2024 · filed 26 November 2024
- was granted 40,000 shares of Beyond Air (a derivative holding)SEC Form 426 November 2024Stock Options (Right to buy) · traded 22 November 2024 · filed 26 November 2024
- returned to the issuer 30,000 shares of Beyond Air (a derivative holding)SEC Form 426 November 2024Stock Options (Right to buy) · traded 22 November 2024 · filed 26 November 2024
- was granted 30,000 shares of Beyond Air (a derivative holding)SEC Form 426 November 2024Stock Options (Right to buy) · traded 22 November 2024 · filed 26 November 2024
- returned to the issuer 25,000 shares of Beyond Air (a derivative holding)SEC Form 426 November 2024Stock Options (Right to buy) · traded 22 November 2024 · filed 26 November 2024
- was granted 25,000 shares of Beyond Air (a derivative holding)SEC Form 426 November 2024Stock Options (Right to buy) · traded 22 November 2024 · filed 26 November 2024
- returned to the issuer 25,000 shares of Beyond Air (a derivative holding)SEC Form 426 November 2024Stock Options (Right to buy) · traded 22 November 2024 · filed 26 November 2024
- was granted 25,000 shares of Beyond Air (a derivative holding)SEC Form 426 November 2024Stock Options (Right to buy) · traded 22 November 2024 · filed 26 November 2024
- returned to the issuer 20,000 shares of Beyond Air (a derivative holding)SEC Form 426 November 2024Stock Options (Right to buy) · traded 22 November 2024 · filed 26 November 2024
- was granted 20,000 shares of Beyond Air (a derivative holding)SEC Form 426 November 2024Stock Options (Right to buy) · traded 22 November 2024 · filed 26 November 2024
- returned to the issuer 25,000 shares of Beyond Air (a derivative holding)SEC Form 426 November 2024Stock Options (Right to buy) · traded 22 November 2024 · filed 26 November 2024
- was granted 25,000 shares of Beyond Air (a derivative holding)SEC Form 426 November 2024Stock Options (Right to buy) · traded 22 November 2024 · filed 26 November 2024
- ▲ bought on the open market 39,266 shares of Beyond AirSEC Form 415 August 2024Common Stock · traded 14 August 2024 · filed 15 August 2024
- was granted 20,000 shares of SAB Biotherapeutics (a derivative holding)SEC Form 417 July 2024Stock Option (right to buy) · traded 15 July 2024 · filed 17 July 2024
- ▼ sold on the open market 22,337 shares of Editas MedicineSEC Form 422 May 2024Common Stock · traded 20 May 2024 · filed 22 May 2024
- was granted 45,000 shares of Beyond Air (a derivative holding)SEC Form 421 March 2024Stock Option (right to buy) · traded 20 March 2024 · filed 21 March 2024
- was granted 106,000 shares of Editas Medicine (a derivative holding)SEC Form 45 March 2024Stock Option (right to buy) · traded 2 March 2024 · filed 5 March 2024
- was granted 35,300 shares of Editas MedicineSEC Form 45 March 2024Common Stock · traded 2 March 2024 · filed 5 March 2024
- was granted 25,966 shares of Editas MedicineSEC Form 45 March 2024Common Stock · traded 2 March 2024 · filed 5 March 2024
- was granted 85,763 shares of Bone Biologics (a derivative holding)SEC Form 420 September 2023Non-Employee Stock Option · traded 18 September 2023 · filed 20 September 2023
- was granted 155,800 shares of Editas Medicine (a derivative holding)SEC Form 418 May 2023Stock Option (right to buy) · traded 17 May 2023 · filed 18 May 2023
- was granted 77,900 shares of Editas MedicineSEC Form 418 May 2023Common Stock · traded 17 May 2023 · filed 18 May 2023
- was granted 25,000 shares of SAB Biotherapeutics (a derivative holding)SEC Form 45 April 2023Employee Stock Option (right to buy) · traded 3 April 2023 · filed 5 April 2023
- was granted 40,000 shares of Beyond Air (a derivative holding)SEC Form 431 March 2023Stock Option (right to buy) · traded 29 March 2023 · filed 31 March 2023
- ▲ bought on the open market 2,000 shares of Beyond AirSEC Form 420 March 2023Common Stock · traded 16 March 2023 · filed 20 March 2023
- was granted 36,845 shares of Bone Biologics (a derivative holding)SEC Form 48 March 2023Non-Employee Stock Option · traded 23 August 2022 · filed 8 March 2023
- returned to the issuer 50,000 shares of Aveo Pharmaceuticals (a derivative holding)SEC Form 419 January 2023Stock Option (Right to Buy) · traded 19 January 2023 · filed 19 January 2023
- returned to the issuer 100,000 shares of Aveo Pharmaceuticals (a derivative holding)SEC Form 419 January 2023Stock Option (Right to Buy) · traded 19 January 2023 · filed 19 January 2023
- returned to the issuer 218,800 shares of Aveo Pharmaceuticals (a derivative holding)SEC Form 419 January 2023Stock Option (Right to Buy) · traded 19 January 2023 · filed 19 January 2023
- was granted 30,000 shares of Beyond Air (a derivative holding)SEC Form 47 March 2022Stock Option (right to buy) · traded 3 March 2022 · filed 7 March 2022
- was granted 2,949 shares of Bone Biologics (a derivative holding)SEC Form 428 February 2022Non-Employee Stock Option · traded 26 October 2021 · filed 28 February 2022
- was granted 8,722 shares of Bone Biologics (a derivative holding)SEC Form 428 February 2022Non-Employee Stock Option · traded 1 January 2022 · filed 28 February 2022
- was granted 218,800 shares of Aveo Pharmaceuticals (a derivative holding)SEC Form 417 February 2022Stock Option (right to buy) · traded 15 February 2022 · filed 17 February 2022
- was granted 100,000 shares of Aveo Pharmaceuticals (a derivative holding)SEC Form 416 April 2021Stock Option (right to buy) · traded 5 February 2021 · filed 16 April 2021
- was granted 25,000 shares of Beyond Air (a derivative holding)SEC Form 48 March 2021Stock Option (right to buy) · traded 4 March 2021 · filed 8 March 2021
- exercised options over 1,171 shares of Beyond AirSEC Form 43 March 2021Common Stock · traded 16 February 2021 · filed 3 March 2021
- exercised options over 1,171 shares of Beyond Air (a derivative holding)SEC Form 43 March 2021Tranche B Warrant (Right to Buy) · traded 16 February 2021 · filed 3 March 2021
- was granted 500,000 shares of Aveo Pharmaceuticals (a derivative holding)SEC Form 48 January 2020Stock Option (right to buy) · traded 6 January 2020 · filed 8 January 2020
- was granted 280,000 shares of Valeritas Holdings (a derivative holding)SEC Form 48 March 2019Employee Stock Option (Right to Buy) · traded 7 March 2019 · filed 8 March 2019
- was granted 363,000 shares of Valeritas Holdings (a derivative holding)SEC Form 420 November 2018Employee Stock Option (Right to Buy) · traded 19 November 2018 · filed 20 November 2018
- was granted 25,000 shares of AIT Therapeutics (a derivative holding)SEC Form 415 August 2018Stock Option (right to buy) · traded 13 August 2018 · filed 15 August 2018
- exercised options over 1,171 shares of AIT TherapeuticsSEC Form 430 April 2018Common Stock · traded 16 February 2018 · filed 30 April 2018
- ▲ bought on the open market 1,171 shares of AIT Therapeutics (a derivative holding)SEC Form 430 April 2018Tranche A Warrant (right to buy) · traded 16 February 2018 · filed 30 April 2018
- ▲ bought on the open market 1,171 shares of AIT Therapeutics (a derivative holding)SEC Form 430 April 2018Tranche B Warrant (right to buy) · traded 16 February 2018 · filed 30 April 2018
- exercised options over 1,171 shares of AIT Therapeutics (a derivative holding)SEC Form 430 April 2018Tranche A Warrant (right to buy) · traded 16 February 2018 · filed 30 April 2018
- was granted 27,000 shares of Valeritas Holdings (a derivative holding)SEC Form 415 February 2018Employee Stock Option (Right to Buy) · traded 13 February 2018 · filed 15 February 2018
- ▲ bought on the open market 1,000 shares of Valeritas HoldingsSEC Form 423 May 2017Common Stock · traded 22 May 2017 · filed 23 May 2017
- ▲ bought on the open market 500 shares of Valeritas HoldingsSEC Form 423 May 2017Common Stock · traded 22 May 2017 · filed 23 May 2017
- ▲ bought on the open market 3,000 shares of Valeritas HoldingsSEC Form 427 March 2017Common Stock · traded 23 March 2017 · filed 27 March 2017
- was granted 73,800 shares of Valeritas Holdings (a derivative holding)SEC Form 427 March 2017Employee Stock Option (Right to Buy) · traded 23 March 2017 · filed 27 March 2017
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.